EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

/PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...

Related Keywords

United States ,Florida ,Watertown ,Massachusetts ,Americans ,American ,Amy Phillips ,Christina Tartaglia ,Equinox Sciences ,Prnewswire Eyepoint Pharmaceuticals Inc ,Nasdaq ,Eyepoint Pharmaceuticals Nasdaq ,American Society Of Retina Specialists ,Green Room Communications ,Eyepoint Pharmaceuticals ,Eyepoint Pharmaceuticals Inc ,Point Pharmaceuticals ,American Society ,Retina Specialists ,Rishi Singh ,Staff Physician ,Cleveland Clinic Florida ,Cleveland Clinic Martin ,Scientific Advisory ,Nancy Lurker ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Nc ,